Wenzhi Tian

This inventor holds 10 USPTO granted patents and 11 published patent applications and 3 EPO patents. Top assignees: Immuneonco Biopharmaceuticals (Shanghai) Inc., Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wenzhi Tian. Retrieved from https://idiyas.com/inventor/wenzhi-tian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

7 out of 7

Immuneonco Biopharmaceuticals (Shanghai) Inc.

patents

3 out of 3

Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd.

patents

Years Active: 2020-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528866 - RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF AND COMPOSITIONS THEREOF. (2026-01-20),

2. 11926675 - Antibodies binding CD24, preparation and use thereof (2024-03-12),

3. 11891449 - Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof (2024-02-06),

4. 11672859 - Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof (2023-06-13),

5. 11613584 - Antibodies binding CD70, preparation and use thereof (2023-03-28),

6. 11453724 - Recombinant bifunctional protein targeting CD47 and HER2 (2022-09-27),

7. 11407841 - Recombinant bi-functional fusion protein and use thereof (2022-08-09),

8. 11407832 - Recombinant protein targeting PD-L1 and VEGF (2022-08-09),

9. 10973878 - Recombinant fusion protein containing an anti-PD-L1 antibody (2021-04-13),

10. 10800821 - Recombinant bi-functional fusion protein and preparation and application therefor (2020-10-13),

Title: Wenzhi Tian: Innovator in Antibody Research

Introduction

Wenzhi Tian is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of nine patents, showcasing his innovative work in antibody research and therapeutic applications.

Latest Patents

Among his latest patents is the development of antibodies binding CD24, which includes a detailed description of an antibody that specifically binds to CD24 or an antigen-binding portion thereof. This patent also covers a nucleic acid molecule encoding the antibody, an expression vector, and a host cell that comprises the nucleic acid molecule. Furthermore, it outlines methods for expressing the antibody and treating diseases associated with CD24 signaling using the antibody or its binding portion. Another notable patent involves recombinant fusion proteins targeting CD47 and CD24. This application provides a recombinant fusion protein that contains an anti-CD24 antibody or an antibody fragment linked to an extracellular Ig-like domain of a signal-regulatory protein (SIRP). The fusion protein is designed to bind to CD47, CD24, and FcR simultaneously, along with methods for producing the protein and treating diseases related to the overexpression of CD47 and/or CD24.

Career Highlights

Wenzhi Tian has worked with notable companies in the biopharmaceutical sector, including Immuneonco Biopharmaceuticals (Shanghai) Inc. and Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. His work in these organizations has contributed to advancements in therapeutic solutions targeting critical cellular pathways.

Collaborations

Wenzhi Tian has collaborated with esteemed colleagues such as Song Li and Dianze Chen, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Wenzhi Tian's innovative work in antibody research and his contributions to the biopharmaceutical industry highlight his role as a leading inventor in the field. His patents reflect a commitment to advancing medical science and improving treatment options for diseases associated with critical cellular signaling pathways.

Profile summary based on public USPTO records.